Cognevity®

Dementia is on the rise—but what if there’s another path and another destination? Alzheimer’s disease is the most common type of Dementia. Traditional medicine for Alzheimer’s usually treats a single symptom and simply slows down the disease progression - i.e. you get worse more slowly. Alzheimer's is complex and involves multiple risk factors, but the latest science shows that it is possible to manage your personalized risk factors with the corresponding multiple lifestyle strategies - leading towards another path and another destination. The earlier you start, the better. It is especially important and critical if you're one of approximately 25% of the population with an increased genetic risk. But it’s never too late to protect your cognitive health. Based in Sydney, Australia, Cognevity® offers services designed to empower individuals, groups, and communities to manage their risk of Alzheimer's disease. We work with adults who have genetic risk factors (including the ApoE4 allele), a family history of Alzheimer's, Subjective Cognitive Impairment (SCI), Mild Cognitive Impairment (MCI), or early Alzheimer's. Our approach is grounded in the comprehensive Bredesen Protocol. Cognevity offers the PreCODE and ReCODE Programs in partnership with Apollo Health, as well as a 'Manage Your Risk of Alzheimer’s' Program that is based on the Bredesen Protocol. For eligible individuals, Cognevity also administers and scores the Montreal Cognitive Assessment (MoCA) for suitable individuals. 'Cognevity' is a portmanteau of 'cognitive' and 'longevity,' symbolizing our commitment to lifelong cognitive health.

Website

www.cognevity.com.au

External link for Cognevity®

Industry

Health and Human Services

Company size

1 employee

Headquarters

Sydney

Type

Privately Held

Founded

2024

Specialties

Health Coaching, Cognitive Health, Alzheimer's Risk Reduction, ReCODE2.0, and Bredesen Protocol